Loading...
Many academic commentators have considered whether healthy people should use cognitive-enhancing drugs, such as modafinil (Nature 2008; 456:702). Thus, a study of the drug’s potential adverse effects is highly topical.
Ten men (mean age, 34), who were nonsmokers and free of psychiatric, major medical, and substance use disorders (SUDs), underwent four PET scans on 2 days after taking placebo or modafinil at clinical doses (200 mg as used for ADHD and 400 mg as used for narcolepsy). The PET scans used labeled ligands for dopamine D2/D3 receptors (DRs) and the dopamine transporter (DAT). Two hours after drug dosing, investigators obtained plasma levels of modafinil.
The researchers found no significant between-dose effects or self-reported mood…